Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05417932 · ClinicalTrials.gov registry record · Phase 1

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

A Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma, sponsored by SCG Cell Therapy Pte..

Recruiting
Registry status
Phase 1
Development phase
46
Enrollment target
6
Study locations

NCT05417932 is a Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma that is actively recruiting participants, run by SCG Cell Therapy Pte.. The registered enrollment target is 46 participants. The trial reports 6 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05417932, a Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma, is actively recruiting participants, sponsored by SCG Cell Therapy Pte..

RECRUITING
Registry status
Phase 1
Development phase
46 participants
Enrollment target
6
Study locations

Study Summary

This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Interventions

  • BIOLOGICAL SCG101

Study Locations (6)

Other

  • Hong Kong is. - Hong Kong
  • Hong Kong NT - Hong Kong
  • Singapore - Singapore
  • Singapore - Singapore

New York

  • New York - New York
  • New York - New York

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2022-10-26
Est. Completion 2025-10
Phase Phase 1

Sponsor

SCG Cell Therapy Pte.

1 total trials

What the Registry Record Tells You About NCT05417932

The ClinicalTrials.gov registry entry for NCT05417932 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCG Cell Therapy Pte., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hepatocellular Carcinoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which SCG101 is the first listed.

NCT05417932 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.

Frequently Asked Questions

What is clinical trial NCT05417932 about?

NCT05417932 is a clinical study titled "A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma". This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

What is the current status of trial NCT05417932?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-10-26. Estimated completion is 2025-10.

What conditions does trial NCT05417932 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma Recurrent, Hepatitis B Virus Related Hepatocellular Carcinoma.

What interventions are being tested in trial NCT05417932?

The interventions under investigation include: SCG101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05417932?

This trial is sponsored by SCG Cell Therapy Pte., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05417932 being conducted?

This trial has 6 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatocellular Carcinoma Recurrent

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.